In a groundbreaking move within the biotechnology sector, Voyager Therapeutics recently announced a strategic licensing deal with Novartis, catapulting its shares up by an impressive 35% in premarket trading. The collaboration involves Novartis making an upfront payment of $100 million to gain exclusive access to Voyager's cutting-edge RNA-based screening...
VYGR has been showing for a while that the momentum is dying. Although MACD may show some signs of reversals in coming weeks but since BTC doesn't look very strong as of now, I could deduce that it will have some effect on VYGR. The VPVR on the right side is showing the same as there has not been much volume traded between here and $9 level. Let's hope it...
VYGR at support for a day trade of 15+% this TP2 should give a pullback for a long swing trade plan
Voyager therapeutics could jump up on another surprise earnings The 50 day Moving average is below the 100 and 200 day moving - volume is up and earnings have amazing earnings up 60% and 1300% these last few quarters so.... it might turn around - I am not buying at this price though. How long can you out perform with your stock falling ? I don't know.
The stock has never been cheaper (except covid crash) so it looks like a nice opportunity for a long. Moreover there is a gap to be filled. Going long with a tight stop - might be a nice reward without too much risk.
we see a Low RSI and a break out is incoming also 50/100/200 moving averages are tightening before a break out. But investors first have to understand that the deal is over but they will rise again
VYGR has reached a strong support area while the RSI has had higher lows indicating accumulation. The MACD is also increasing and is almost positive. Expecting the price to increase steadily soon. Look out for the bull cross of EMA9 of EMA21. This will accelerate the price rise. The next earnings are on Feb 26.
Coming up from a recent trend change after a bear trend since march 18 Bullish news, Three EMA crossover, and above ichimoku clouds Potential retracement can happen nevertheless long term this is looking strong
VYGR continues to impress to the upside - Congrats if you bought it recently!
Dark pools may be responsible for recent overselling w/2 near-term catalysts: 4/25 (presentation of its Phase 1b PD drug results at AAN Annual Meeting), 5/11 (earnings). Its PD (VY-AADC01) will shake the market if its phase 1b results can be replicated. Price should correct to $14-15 after a couple weeks. NASDAQ:VYGR